fulvestrant has been researched along with Local Neoplasm Recurrence in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (11.32) | 29.6817 |
| 2010's | 21 (39.62) | 24.3611 |
| 2020's | 26 (49.06) | 2.80 |
| Authors | Studies |
|---|---|
| Asakawa, H; Baba, N; Nakamura, A; Park, K; Shigekawa, T | 1 |
| Abdulkareem, NM; Bae, L; Bhat, R; Cataldo, ML; De Angelis, C; Fu, X; Nanda, S; Schiff, R; Thangavel, H; Trivedi, MV; Vasaikar, S; Zhang, B | 1 |
| Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Ito, Y; Kawaguchi, H; Masuda, N; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Takano, T; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, H; Yamashita, T; Yotsumoto, D | 2 |
| Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M | 1 |
| Aithal, KB; Albacker, LA; Banka, D; Bolduc, DM; Furman, C; Hao, MH; Irwin, S; Kim, A; Korpal, M; Larsen, N; Montesion, M; Moriarty, AD; Murugesan, K; Nguyen, TV; Prajapati, S; Puyang, X; Rimkunas, V; Sahmoud, T; Vaillancourt, FH; Wick, MJ; Wu, ZJ; Yao, S; Zeng, H; Zhang, X; Zhang, Z; Zheng, GZ; Zhu, P | 1 |
| Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; de Bruin, EC; Foxley, A; Howell, SJ; Ingarfield, K; Jones, RH; Meissner, M; Moon, S; Morgan, S; Schiavon, G; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Lauchle, JO; Metcalfe, C | 1 |
| Belka, GK; Chen, S; Chodosh, LA; DeMichele, A; Makhlin, I; Mesaros, C; Pan, TC; Pant, DK; Paul, MR; Sreekumar, A; Sterner, CJ; Wang, D; Xu, P | 1 |
| Alexis, MN; Chatziioannou, A; Ganou, V; Gkotsi, EF; Meligova, AK; Mitsiou, DJ; Papadodima, O; Pilalis, E; Siakouli, D; Stasinopoulou, S; Xenopoulou, DS; Zoumpouli, M | 1 |
| Cortes, J; Dalenc, F; de Bruin, EC; Foxley, A; Gomez Moreno, HL; Grinsted, L; Howell, SJ; Hu, X; Jhaveri, K; Krivorotko, P; Loibl, S; Morales Murillo, S; Okera, M; Oliveira, M; Park, YH; Rugo, HS; Schiavon, G; Sohn, J; Toi, M; Tokunaga, E; Turner, NC; Yousef, S; Zhukova, L | 1 |
| Olufade, T; Schwartzberg, LS; Skinner, KE; Walker, MS | 1 |
| Bun, A; Fujimoto, Y; Fukui, R; Higuchi, T; Imamura, M; Miyagawa, Y; Miyoshi, Y; Ozawa, H; Sata, A | 1 |
| Almotlak, AA; Farooqui, M; Siegfried, JM | 1 |
| Brufsky, AM; Nasrazadani, A | 1 |
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Jiang, YZ; Liu, XY; Shao, ZM; Wang, H | 1 |
| Dekker, TJA | 1 |
| Kim, DH; Ludmir, EB; McCaw, ZR; Tian, L; Wei, LJ | 1 |
| Carucci, M; Casbard, A; Foxley, A; Howell, SJ; Jones, RH | 1 |
| Cao, Y; Ding, J; Fu, W; Guo, Y; Jiang, X; Li, K | 1 |
| Li, Z; Liu, Z; Shao, Z; Song, C; Wang, X; Xiao, Z; Yang, X; Zhang, K | 1 |
| Cortés, J; Cui, N; De Laurentiis, M; Dent, S; Diéras, V; Drullinsky, P; Harbeck, N; He, J; Hsu, JY; Im, YH; Jacot, W; Krop, IE; Schimmoller, F; Sousa, S; Wilson, TR | 1 |
| Aja, J; Brantley, E; Campbell, P; Davis, MB; Loaiza-Perez, A; Mavingire, N; Wooten, J | 1 |
| Ortmann, O; Riedmeier, M; Schüler-Toprak, S; Skrzypczak, M; Treeck, O | 1 |
| Akiyama, Y; Doi, S; Hagihara, K; Matsushita, K; Motoki, Y; Nakaguchi, K; Sakisaka, H | 1 |
| Abe, M; Chiba, R; Ishiguro, A; Ito, K; Kato, H; Kubota, R; Matsunami, O; Narita, Y; Ohigashi, A; Tanimoto, A | 1 |
| Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Ito, Y; Kawaguchi, H; Masuda, N; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, T | 1 |
| Akiyoshi, S; Ijichi, H; Ishida, M; Koga, C; Koi, Y; Masuda, T; Nakamura, Y; Ohno, S; Tokunaga, E | 1 |
| Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E | 1 |
| E Nagai, S; Futsuhara, K; Hata, S; Inoue, K; Kaneko, S; Kimizuka, K; Kurosumi, M; Nakano, S; Saito, T; Sakurai, T; Yamada, H | 1 |
| Breitbach, GP; Camara, O; Emons, G; Finas, D; Günthert, A; Kölbl, H; Reimer, T; Rensing, K; Strauss, HG; Thiel, FC | 1 |
| Argenta, PA; Faratian, D; Geller, MA; Harrison, D; Kay, C; Langdon, SP; Sueblinvong, T; Um, I | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Black, EP; Elledge, R; Kadamyan-Melkumian, V; Massarweh, S; Romond, E; Shelton, B; Stevens, M; Van Meter, E | 1 |
| Anzeneder, T; Benes, V; Burwinkel, B; Büttner, R; Deuschle, U; Heck, S; Lichter, P; Nicholson, RI; Sauter, G; Schlotter, M; Schneeweiss, A; Schroeter, P; Simon, R; Sinn, HP; Thewes, V; Zapatka, M | 1 |
| Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Laenkholm, AV; Larsen, SL; Lykkesfeldt, AE; Rasmussen, BB; Yde, CW | 1 |
| Akiyama, F; Araki, K; Horii, R; Ishida, N; Ito, Y; Ohno, S; Takahashi, S | 1 |
| Amir, E; Gordon, V; Graham, J; Grenier, D; Niraula, S; Pitz, M | 1 |
| Bartlett, CH; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Harbeck, N; Im, SA; Iwata, H; Jiang, Y; Koehler, M; Loi, S; Masuda, N; Ro, J; Slamon, D; Theall, KP; Turner, NC; Verma, S; Zhang, K | 1 |
| de Boer, R; Derynck, M; Dickler, M; Ellis, M; Forero-Torres, A; Ganju, V; Gendreau, S; He, J; Johnston, S; Krop, IE; Lackner, M; Lee, SC; Levy, G; Mayer, IA; Melichar, B; Morales, S; Perez, EA; Petrakova, K; Piccart, M; Qiu, J; Schmid, P; Vallentin, S; Winer, E; Yardley, DA | 1 |
| Beyer, JM; Dittmer, A; Dittmer, J; Hellwig, V; Ignatov, A; Kalinski, T; Kirkegaard, T; Lange, T; Leyh, B; Lykkesfeldt, AE; Nass, N; Weiβenborn, C | 1 |
| Arachchige-Don, AP; Donaldson, MS; Horne, MC; Patriarchi, T; Zimmermann, M | 1 |
| Argenta, PA; Carson, LF; Downs, LS; Geller, MA; Ghebre, R; Jonson, AL; Judson, PL; Thomas, SG | 1 |
| Borges, VF; Kabos, P | 1 |
| Bonebrake, A; Covens, AL; Filiaci, V; Gersell, D; Lee, YC; Lutman, CV | 1 |
| Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG | 1 |
| Chen, L; Kamano, S; Sato, T; Yano, S | 1 |
| Harwood, KV | 1 |
| Jakesz, R | 1 |
| Amant, F; Bines, J; Brufsky, A; Buzdar, A; Chia, S; Federico, M; Fein, L; Gradishar, W; Lowe, E; Mauriac, L; Piccart, M; Possinger, K; Rennie, P; Robertson, JF; Romieu, G; Sapunar, F | 1 |
| Bliss, JM; Coombes, G; Dodwell, D; Johnston, S; Kilburn, LS | 1 |
| Nomura, Y | 1 |
6 review(s) available for fulvestrant and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Comparative Effectiveness Research; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic | 2016 |
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Delivery Systems; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2010 |
[Pharmacological and clinical profiles of Fulvestrant (Faslodex(®)) in the treatment of advanced or recurrenced breast cancer].
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Mice; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Rats; Receptors, Estrogen | 2012 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
[Pure antiestrogen for treatment of advanced breast cancers].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Tamoxifen; Treatment Outcome | 2000 |
14 trial(s) available for fulvestrant and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomar
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Male; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2023 |
A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Receptor, ErbB-2; Receptors, Cell Surface; Retrospective Studies | 2019 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Imidazoles; Neoplasm Recurrence, Local; Oxazepines; Phosphatidylinositol 3-Kinases; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen | 2019 |
Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.
Topics: Antineoplastic Agents, Hormonal; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tissue Array Analysis | 2013 |
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure | 2014 |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas
Topics: Adult; Aged; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Piperazines; Pyridines; Receptor, ErbB-2; Treatment Outcome | 2016 |
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2016 |
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer.
Topics: Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Bone and Bones; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peptides | 2009 |
Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease-Free Survival; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptors, Estrogen; Receptors, Progesterone | 2011 |
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Placebos; Postmenopause; Quality of Life; Receptors, Estrogen | 2008 |
33 other study(ies) available for fulvestrant and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endocrine Gland Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Recurrence, Local; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Receptors, Neuropeptide Y; Tamoxifen | 2022 |
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2022 |
[A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lung Neoplasms; Mastectomy; Neoplasm Recurrence, Local | 2022 |
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indazoles; Neoplasm Recurrence, Local; Pyridines | 2022 |
Clinical Translation: Targeting the Estrogen Receptor.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Receptors, Estrogen; Tamoxifen | 2022 |
PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
Topics: Animals; Drug Resistance, Neoplasm; Estrogens; Fulvestrant; Lapatinib; Mice; Neoplasm Recurrence, Local; Receptor, ErbB-2; Receptors, Progesterone | 2023 |
ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Protein Isoforms; Tamoxifen; Tretinoin | 2023 |
Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Databases, Factual; Disease-Free Survival; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Receptor, ErbB-2; Retrospective Studies | 2020 |
Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Fulvestrant; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2020 |
Capivasertib inhibits a key pathway in metastatic breast cancer.
Topics: Aromatase; Breast Neoplasms; Estrogens; Fulvestrant; Humans; Neoplasm Recurrence, Local | 2020 |
[Challenges and countermeasures in the treatment of luminal breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Fulvestrant; Humans; Neoplasm Recurrence, Local; Receptors, Estrogen; Vascular Endothelial Growth Factor A | 2020 |
Fulvestrant plus capivasertib for metastatic breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Estrogens; Fulvestrant; Humans; Neoplasm Recurrence, Local | 2020 |
Fulvestrant plus capivasertib for metastatic breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Estrogens; Fulvestrant; Humans; Neoplasm Recurrence, Local | 2020 |
Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
Topics: Aromatase; Aromatase Inhibitors; Estrogens; Fulvestrant; Humans; Neoplasm Recurrence, Local | 2020 |
Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Narrative Medicine; Neoplasm Recurrence, Local; Re-Irradiation; Receptors, Estrogen | 2020 |
Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Hypophysectomy; Male; MAP Kinase Signaling System; Middle Aged; Neoplasm Recurrence, Local; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Rats; Receptors, Prolactin; Young Adult | 2020 |
Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2021 |
Icb-1 expression inhibits growth and fulvestrant response of breast cancer cells and affects survival of breast cancer patients.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Reverse Transcriptase Polymerase Chain Reaction | 2021 |
[Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report].
Topics: Aged; Aminopyridines; Axilla; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Neoplasm Recurrence, Local | 2020 |
[A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyridines | 2021 |
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Treatment Failure; Treatment Outcome | 2017 |
Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptors, Steroid; Treatment Outcome; Viscera | 2018 |
Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prospective Studies; Receptors, Estrogen; Retrospective Studies; Time Factors; Treatment Outcome | 2019 |
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Nuclear Receptor Coactivator 3; Receptors, Estrogen; Tamoxifen | 2015 |
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aurora Kinase B; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mitosis; Neoplasm Recurrence, Local; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Survival Analysis; Tamoxifen | 2015 |
Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Retrospective Studies; Time-to-Treatment | 2015 |
Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response.
Topics: Biomarkers, Pharmacological; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Integrin beta1; MCF-7 Cells; Membrane Proteins; Neoplasm Recurrence, Local; RNA | 2016 |
Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin G2; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Knockdown Techniques; Humans; Metformin; Mitogen-Activated Protein Kinase Kinases; Neoplasm Recurrence, Local; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-raf; Receptors, Estrogen; Retinoblastoma Protein; RNA Interference; Signal Transduction; Survival Analysis; Up-Regulation | 2016 |
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Receptors, Estrogen | 2008 |